NCT00000901已完成1 期
A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection
National Institute of Allergy and Infectious Diseases (NIAID)38 个研究点 分布在 2 个国家目标入组 24 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 38
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to HIV-infected children. IDV will be given either as a powder mixed into applesauce or as capsules given on an empty stomach.
详细描述
In this multicenter, open-label study patients receive a combined drug regimen of indinavir, stavudine, and lamivudine over 48 weeks. Patients are evaluated at Weeks 0, 2, 4, every 4 weeks until Week 24, and every 8 weeks thereafter until study completion. [AS PER AMENDMENT 4/27/99: The study has been extended for an additional 48 weeks for a total of 96 weeks.]
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 3 Years 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (38)
Loading locations...
相似试验
已完成
2 期
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease InhibitorsHIV InfectionsNCT00002361Merck Sharp & Dohme LLC30
已完成
4 期
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected AdultsHIV InfectionsNCT00004585Glaxo Wellcome40
已完成
2 期
A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionHIV InfectionsNCT00002233Glaxo Wellcome30
已完成
不适用
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected PatientsHIV InfectionsNCT00002375Merck Sharp & Dohme LLC24
终止
2 期
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002418Bristol-Myers Squibb25